Bioqual (OTCMKTS:BIOQ) Issues Earnings Results

Bioqual (OTCMKTS:BIOQ) released its quarterly earnings data on Thursday. The company reported $0.15 earnings per share for the quarter, Zacks reports. Bioqual had a return on equity of 2.01% and a net margin of 1.56%.The company had revenue of $10.98 million for the quarter.

Bioqual Price Performance

Bioqual stock opened at $38.50 on Friday. The firm has a market capitalization of $34.27 million, a P/E ratio of 47.53 and a beta of -0.19. The stock has a fifty day moving average price of $38.51 and a two-hundred day moving average price of $40.43. Bioqual has a 52-week low of $33.00 and a 52-week high of $66.10.

About Bioqual

Bioqual, Inc is a U.S.-based contract research organization specializing in preclinical immunology and pharmacology services for the biopharmaceutical industry. The company offers a range of in vivo and in vitro testing solutions designed to support vaccine development, immuno-oncology programs and other therapeutic modalities. Bioqual’s service portfolio encompasses assay development, safety and efficacy studies, biomarker analysis and specialized immunogenicity assessments.

Leveraging proprietary humanized animal models and nonhuman primate research platforms, Bioqual helps clients evaluate biological activity, toxicity and pharmacokinetics of investigational compounds.